Business Context and Reporting Period
Company: InspireMD, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: July 1, 2024
Reporting Period: Specific event date (July 1, 2024)
This filing reports the completion of the full exercise of the Company's Series H warrants, originally issued as part of a private placement financing consummated on May 15, 2023.
Key Financial Metrics
| Metric | Value |
|---|---|
| Gross Proceeds from Warrant Exercise | $17.9 million |
| Net Proceeds (after fees) | $16.9 million |
| Warrants Exercised | 12.9 million Series H warrants |
| Common Shares Issued | 292,996 |
| Pre-funded Warrants Issued | 12,599,343 |
| Exercise Price (Common) | $1.3827 per share |
| Exercise Price (Pre-funded) | $1.3826 per warrant |
Note: This filing does not provide data on revenue, profit, operating cash flow, margins, or total debt levels.
Material Changes
- Capital Structure: The Company converted 12.9 million Series H warrants into a mix of common stock and pre-funded warrants.
- Liquidity: The transaction generated $17.9 million in gross cash proceeds, significantly increasing the Company's available liquidity.
Outlook and Management Commentary
Management intends to utilize the net proceeds of $16.9 million to advance the development and commercialization of two key product lines:
- CGuard Prime Transfemoral (CAS) delivery system.
- SwitchGuard trans carotid (TCAR) neuroprotection system (NPS).
The filing includes a press release (Exhibit 99.1) detailing the announcement but does not contain specific forward-looking financial guidance or risk factor updates beyond the standard incorporation by reference.
Investor Verification Checklist
- Verify the dilution impact of the issuance of 292,996 common shares and 12,599,343 pre-funded warrants on existing shareholders.
- Confirm the specific allocation of the $16.9 million net proceeds between the CGuard Prime and SwitchGuard projects.
- Review the terms of the pre-funded warrants to understand the timeline and conditions for their conversion into common stock.
- Check subsequent filings for updates on the development milestones of the CAS and TCAR systems funded by this capital raise.